{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T06:54:32Z","timestamp":1779260072325,"version":"3.51.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,8,5]],"date-time":"2015-08-05T00:00:00Z","timestamp":1438732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,8,5]],"date-time":"2015-08-05T00:00:00Z","timestamp":1438732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Adipocytes are the primary cells in adipose tissue and adipocyte dysfunction causes lipodystrophy, obesity and diabetes. The dipeptidyl peptidase (DPP) 4 family includes four enzymes, DPP4, DPP8, DPP9 and fibroblast activation protein (FAP). DPP4 family inhibitors have been used for the treatment of type 2 diabetes patients, but their role in adipocyte formation are poorly understood. Here we demonstrate that the DPP8\/9 selective inhibitor 1G244 blocks adipogenesis in preadipocyte 3T3-L1 and 3T3-F422A, while DPP4 and FAP inhibitors have no effect. In addition, knockdown of DPP8 or DPP9 significantly impairs adipocyte differentiation in preadipocytes. We further uncovered that blocking the expression or activities of DPP8 and DPP9 attenuates PPAR\u03b32 induction during preadipocyte differentiation. Addition of PPAR\u03b3 agonist thiazolidinediones (TZDs), or ectopic expression of PPAR\u03b32, is able to rescue the adipogenic defect caused by DPP8\/9 inhibition in preadipocytes. These results indicate the importance of DPP8 and DPP9 on adipogenesis.<\/jats:p>","DOI":"10.1038\/srep12348","type":"journal-article","created":{"date-parts":[[2015,8,5]],"date-time":"2015-08-05T09:48:28Z","timestamp":1438768108000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Inhibition of dipeptidyl peptidase 8\/9 impairs preadipocyte differentiation"],"prefix":"10.1038","volume":"5","author":[{"given":"Ruijun","family":"Han","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Bachovchin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zofia","family":"Zukowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John W.","family":"Osborn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,5]]},"reference":[{"key":"BFsrep12348_CR1","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1056\/NEJMsr043743","volume":"352","author":"SJ Olshansky","year":"2005","unstructured":"Olshansky, S. J. et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med 352, 1138\u20131145, 10.1056\/NEJMsr043743 (2005).","journal-title":"N Engl J Med"},{"key":"BFsrep12348_CR2","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nature05487","volume":"444","author":"LF Van Gaal","year":"2006","unstructured":"Van Gaal, L. F., Mertens, I. L. & De Block, C. E. Mechanisms linking obesity with cardiovascular disease. Nature 444, 875\u2013880, 10.1038\/nature05487 (2006).","journal-title":"Nature"},{"key":"BFsrep12348_CR3","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/nature05482","volume":"444","author":"SE Kahn","year":"2006","unstructured":"Kahn, S. E., Hull, R. L. & Utzschneider, K. M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444, 840\u2013846, 10.1038\/nature05482 (2006).","journal-title":"Nature"},{"key":"BFsrep12348_CR4","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/nrm2066","volume":"7","author":"ED Rosen","year":"2006","unstructured":"Rosen, E. D. & MacDougald, O. A. Adipocyte differentiation from the inside out. Nature reviews. Molecular cell biology 7, 885\u2013896, 10.1038\/nrm2066 (2006).","journal-title":"Nature reviews. Molecular cell biology"},{"key":"BFsrep12348_CR5","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1126\/science.7624777","volume":"269","author":"JL Halaas","year":"1995","unstructured":"Halaas, J. L. et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269, 543\u2013546 (1995).","journal-title":"Science"},{"key":"BFsrep12348_CR6","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/90984","volume":"7","author":"T Yamauchi","year":"2001","unstructured":"Yamauchi, T. et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature medicine 7, 941\u2013946, 10.1038\/90984 (2001).","journal-title":"Nature medicine"},{"key":"BFsrep12348_CR7","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/35053000","volume":"409","author":"CM Steppan","year":"2001","unstructured":"Steppan, C. M. et al. The hormone resistin links obesity to diabetes. Nature 409, 307\u2013312, 10.1038\/35053000 (2001).","journal-title":"Nature"},{"key":"BFsrep12348_CR8","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nm.3159","volume":"19","author":"M Ahmadian","year":"2013","unstructured":"Ahmadian, M. et al. PPARgamma signaling and metabolism: the good, the bad and the future. Nature medicine 19, 557\u2013566, 10.1038\/nm.3159 (2013).","journal-title":"Nature medicine"},{"key":"BFsrep12348_CR9","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1101\/gad.3.9.1323","volume":"3","author":"RJ Christy","year":"1989","unstructured":"Christy, R. J. et al. Differentiation-induced gene expression in 3T3-L1 preadipocytes: CCAAT\/enhancer binding protein interacts with and activates the promoters of two adipocyte-specific genes. Genes & development 3, 1323\u20131335 (1989).","journal-title":"Genes & development"},{"key":"BFsrep12348_CR10","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.2337\/diabetes.53.5.1243","volume":"53","author":"KT Dalen","year":"2004","unstructured":"Dalen, K. T. et al. Adipose tissue expression of the lipid droplet-associating proteins S3-12 and perilipin is controlled by peroxisome proliferator-activated receptor-gamma. Diabetes 53, 1243\u20131252 (2004).","journal-title":"Diabetes"},{"key":"BFsrep12348_CR11","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.cmet.2011.02.014","volume":"13","author":"CJ Villanueva","year":"2011","unstructured":"Villanueva, C. J. et al. TLE3 is a dual-function transcriptional coregulator of adipogenesis. Cell metabolism 13, 413\u2013427, 10.1016\/j.cmet.2011.02.014 (2011).","journal-title":"Cell metabolism"},{"key":"BFsrep12348_CR12","doi-asserted-by":"publisher","first-page":"12953","DOI":"10.1074\/jbc.270.22.12953","volume":"270","author":"JM Lehmann","year":"1995","unstructured":"Lehmann, J. M. et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). The Journal of biological chemistry 270, 12953\u201312956 (1995).","journal-title":"The Journal of biological chemistry"},{"key":"BFsrep12348_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1042\/CS20090047","volume":"118","author":"M Kirby","year":"2010","unstructured":"Kirby, M., Yu, D. M., O\u2019Connor, S. & Gorrell, M. D. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin Sci (Lond) 118, 31\u201341, 10.1042\/CS20090047 (2010).","journal-title":"Clin Sci (Lond)"},{"key":"BFsrep12348_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2165\/00024677-200201020-00005","volume":"1","author":"LL Baggio","year":"2002","unstructured":"Baggio, L. L. & Drucker, D. J. Harnessing the therapeutic potential of glucagon-like peptide-1: a critical review. Treatments in endocrinology 1, 117\u2013125 (2002).","journal-title":"Treatments in endocrinology"},{"key":"BFsrep12348_CR15","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2174\/092986730611220401163238","volume":"6","author":"JJ Holst","year":"1999","unstructured":"Holst, J. J. Glucagon-like peptide-1, a gastrointestinal hormone with a pharmaceutical potential. Current medicinal chemistry 6, 1005\u20131017 (1999).","journal-title":"Current medicinal chemistry"},{"key":"BFsrep12348_CR16","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.2337\/db05-1602","volume":"55","author":"J Mu","year":"2006","unstructured":"Mu, J. et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55, 1695\u20131704, 10.2337\/db05-1602 (2006).","journal-title":"Diabetes"},{"key":"BFsrep12348_CR17","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.2337\/dc07-0228","volume":"30","author":"DJ Drucker","year":"2007","unstructured":"Drucker, D. J. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes care 30, 1335\u20131343, 10.2337\/dc07-0228 (2007).","journal-title":"Diabetes care"},{"key":"BFsrep12348_CR18","doi-asserted-by":"publisher","first-page":"6825","DOI":"10.1073\/pnas.0631828100","volume":"100","author":"SL Conarello","year":"2003","unstructured":"Conarello, S. L. et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proceedings of the National Academy of Sciences of the United States of America 100, 6825\u20136830, 10.1073\/pnas.0631828100 (2003).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"BFsrep12348_CR19","doi-asserted-by":"publisher","first-page":"190","DOI":"10.2337\/db07-1202","volume":"57","author":"BJ Lamont","year":"2008","unstructured":"Lamont, B. J. & Drucker, D. J. Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice. Diabetes 57, 190\u2013198, 10.2337\/db07-1202 (2008).","journal-title":"Diabetes"},{"key":"BFsrep12348_CR20","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.2337\/dc07-0233","volume":"30","author":"B Ahren","year":"2007","unstructured":"Ahren, B. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Diabetes care 30, 1344\u20131350, 10.2337\/dc07-0233 (2007).","journal-title":"Diabetes care"},{"key":"BFsrep12348_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/0-306-46826-3_10","volume":"477","author":"CA Abbott","year":"2000","unstructured":"Abbott, C. A., Yu, D., McCaughan, G. W. & Gorrell, M. D. Post-proline-cleaving peptidases having DP IV like enzyme activity. Post-proline peptidases. Advances in experimental medicine and biology 477, 103\u2013109, 10.1007\/0-306-46826-3_10 (2000).","journal-title":"Advances in experimental medicine and biology"},{"key":"BFsrep12348_CR22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.bbaexp.2004.03.010","volume":"1679","author":"K Ajami","year":"2004","unstructured":"Ajami, K., Abbott, C. A., McCaughan, G. W. & Gorrell, M. D. Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity. Biochimica et biophysica acta 1679, 18\u201328, 10.1016\/j.bbaexp.2004.03.010 (2004).","journal-title":"Biochimica et biophysica acta"},{"key":"BFsrep12348_CR23","doi-asserted-by":"publisher","first-page":"27211","DOI":"10.1074\/jbc.M109.041871","volume":"284","author":"R Geiss-Friedlander","year":"2009","unstructured":"Geiss-Friedlander, R. et al. The cytoplasmic peptidase DPP9 is rate-limiting for degradation of proline-containing peptides. The Journal of biological chemistry 284, 27211\u201327219, 10.1074\/jbc.M109.041871 (2009).","journal-title":"The Journal of biological chemistry"},{"key":"BFsrep12348_CR24","doi-asserted-by":"publisher","first-page":"6005","DOI":"10.1021\/jm800390n","volume":"51","author":"BA Connolly","year":"2008","unstructured":"Connolly, B. A. et al. Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potency and in vivo efficacy and safety. Journal of medicinal chemistry 51, 6005\u20136013, 10.1021\/jm800390n (2008).","journal-title":"Journal of medicinal chemistry"},{"key":"BFsrep12348_CR25","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.2337\/diabetes.54.10.2988","volume":"54","author":"GR Lankas","year":"2005","unstructured":"Lankas, G. R. et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 54, 2988\u20132994 (2005).","journal-title":"Diabetes"},{"key":"BFsrep12348_CR26","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/leu.2013.9","volume":"27","author":"PA Spagnuolo","year":"2013","unstructured":"Spagnuolo, P. A. et al. Inhibition of intracellular dipeptidyl peptidases 8 and 9 enhances parthenolide\u2019s anti-leukemic activity. Leukemia 27, 1236\u20131244, 10.1038\/leu.2013.9 (2013).","journal-title":"Leukemia"},{"key":"BFsrep12348_CR27","doi-asserted-by":"publisher","first-page":"27494","DOI":"10.1074\/jbc.M111.224089","volume":"286","author":"C Lu","year":"2011","unstructured":"Lu, C. et al. Dipeptidyl peptidases as survival factors in Ewing sarcoma family of tumors: implications for tumor biology and therapy. The Journal of biological chemistry 286, 27494\u201327505, 10.1074\/jbc.M111.224089 (2011).","journal-title":"The Journal of biological chemistry"},{"key":"BFsrep12348_CR28","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1369\/jhc.7A7319.2007","volume":"56","author":"J Schade","year":"2008","unstructured":"Schade, J. et al. Regulation of expression and function of dipeptidyl peptidase 4 (DP4), DP8\/9 and DP10 in allergic responses of the lung in rats. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 56, 147\u2013155, 10.1369\/jhc.7A7319.2007 (2008).","journal-title":"The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society"},{"key":"BFsrep12348_CR29","doi-asserted-by":"publisher","first-page":"13936","DOI":"10.1074\/jbc.M112.445841","volume":"288","author":"CH Wilson","year":"2013","unstructured":"Wilson, C. H. et al. Identifying natural substrates for dipeptidyl peptidases 8 and 9 using terminal amine isotopic labeling of substrates (TAILS) reveals in vivo roles in cellular homeostasis and energy metabolism. The Journal of biological chemistry 288, 13936\u201313949, 10.1074\/jbc.M112.445841 (2013).","journal-title":"The Journal of biological chemistry"},{"key":"BFsrep12348_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1101\/gad.953802","volume":"16","author":"D Ren","year":"2002","unstructured":"Ren, D., Collingwood, T. N., Rebar, E. J., Wolffe, A. P. & Camp, H. S. PPARgamma knockdown by engineered transcription factors: exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis. Genes & development 16, 27\u201332, 10.1101\/gad.953802 (2002).","journal-title":"Genes & development"},{"key":"BFsrep12348_CR31","doi-asserted-by":"publisher","first-page":"41925","DOI":"10.1074\/jbc.M206950200","volume":"277","author":"E Mueller","year":"2002","unstructured":"Mueller, E. et al. Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor gamma isoforms. The Journal of biological chemistry 277, 41925\u201341930, 10.1074\/jbc.M206950200 (2002).","journal-title":"The Journal of biological chemistry"},{"key":"BFsrep12348_CR32","doi-asserted-by":"publisher","first-page":"16271","DOI":"10.1073\/pnas.1109409108","volume":"108","author":"AG Cristancho","year":"2011","unstructured":"Cristancho, A. G. et al. Repressor transcription factor 7-like 1 promotes adipogenic competency in precursor cells. Proceedings of the National Academy of Sciences of the United States of America 108, 16271\u201316276, 10.1073\/pnas.1109409108 (2011).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"BFsrep12348_CR33","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1101\/gad.5.9.1538","volume":"5","author":"Z Cao","year":"1991","unstructured":"Cao, Z., Umek, R. M. & McKnight, S. L. Regulated expression of three C\/EBP isoforms during adipose conversion of 3T3-L1 cells. Genes & development 5, 1538\u20131552 (1991).","journal-title":"Genes & development"},{"key":"BFsrep12348_CR34","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1101\/gad.9.2.168","volume":"9","author":"WC Yeh","year":"1995","unstructured":"Yeh, W. C., Cao, Z., Classon, M. & McKnight, S. L. Cascade regulation of terminal adipocyte differentiation by three members of the C\/EBP family of leucine zipper proteins. Genes & development 9, 168\u2013181 (1995).","journal-title":"Genes & development"},{"key":"BFsrep12348_CR35","doi-asserted-by":"publisher","first-page":"12867","DOI":"10.1074\/jbc.M410515200","volume":"280","author":"T Mori","year":"2005","unstructured":"Mori, T. et al. Role of Kruppel-like factor 15 (KLF15) in transcriptional regulation of adipogenesis. The Journal of biological chemistry 280, 12867\u201312875, 10.1074\/jbc.M410515200 (2005).","journal-title":"The Journal of biological chemistry"},{"key":"BFsrep12348_CR36","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1126\/science.290.5489.134","volume":"290","author":"Q Tong","year":"2000","unstructured":"Tong, Q. et al. Function of GATA transcription factors in preadipocyte-adipocyte transition. Science 290, 134\u2013138 (2000).","journal-title":"Science"},{"key":"BFsrep12348_CR37","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1128\/MCB.25.2.706-715.2005","volume":"25","author":"Q Tong","year":"2005","unstructured":"Tong, Q., Tsai, J., Tan, G., Dalgin, G. & Hotamisligil, G. S. Interaction between GATA and the C\/EBP family of transcription factors is critical in GATA-mediated suppression of adipocyte differentiation. Molecular and cellular biology 25, 706\u2013715, 10.1128\/MCB.25.2.706-715.2005 (2005).","journal-title":"Molecular and cellular biology"},{"key":"BFsrep12348_CR38","first-page":"264","volume":"69 Suppl 1","author":"Y Oishi","year":"2011","unstructured":"Oishi, Y., Manabe, I. & Nagai, R. [Kruppel-like family of transcription factor 5 (KLF5). KLF5 is a key regulator of adipocyte differentiation]. Nihon rinsho. Japanese journal of clinical medicine 69 Suppl 1, 264\u2013268 (2011).","journal-title":"Japanese journal of clinical medicine"},{"key":"BFsrep12348_CR39","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.bcp.2009.03.032","volume":"78","author":"JJ Wu","year":"2009","unstructured":"Wu, J. J. et al. Biochemistry, pharmacokinetics and toxicology of a potent and selective DPP8\/9 inhibitor. Biochemical pharmacology 78, 203\u2013210, 10.1016\/j.bcp.2009.03.032 (2009).","journal-title":"Biochemical pharmacology"},{"key":"BFsrep12348_CR40","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1111\/j.1463-1326.2008.00860.x","volume":"10","author":"BF Burkey","year":"2008","unstructured":"Burkey, B. F. et al. Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited. Diabetes, obesity & metabolism 10, 1057\u20131061, 10.1111\/j.1463-1326.2008.00860.x (2008).","journal-title":"Diabetes, obesity & metabolism"},{"key":"BFsrep12348_CR41","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.clpt.2005.09.002","volume":"78","author":"GA Herman","year":"2005","unstructured":"Herman, G. A. et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clinical pharmacology and therapeutics 78, 675\u2013688, 10.1016\/j.clpt.2005.09.002 (2005).","journal-title":"Clinical pharmacology and therapeutics"},{"key":"BFsrep12348_CR42","doi-asserted-by":"publisher","first-page":"5025","DOI":"10.1021\/jm050261p","volume":"48","author":"DJ Augeri","year":"2005","unstructured":"Augeri, D. J. et al. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Journal of medicinal chemistry 48, 5025\u20135037, 10.1021\/jm050261p (2005).","journal-title":"Journal of medicinal chemistry"},{"key":"BFsrep12348_CR43","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1210\/jc.2003-031907","volume":"89","author":"B Ahren","year":"2004","unstructured":"Ahren, B. et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes. The Journal of clinical endocrinology and metabolism 89, 2078\u20132084, 10.1210\/jc.2003-031907 (2004).","journal-title":"The Journal of clinical endocrinology and metabolism"},{"key":"BFsrep12348_CR44","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1517\/13543780903463862","volume":"19","author":"CF Deacon","year":"2010","unstructured":"Deacon, C. F. & Holst, J. J. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert opinion on investigational drugs 19, 133\u2013140, 10.1517\/13543780903463862 (2010).","journal-title":"Expert opinion on investigational drugs"},{"key":"BFsrep12348_CR45","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1021\/jm070104l","volume":"50","author":"J Feng","year":"2007","unstructured":"Feng, J. et al. Discovery of alogliptin: a potent, selective, bioavailable and efficacious inhibitor of dipeptidyl peptidase IV. Journal of medicinal chemistry 50, 2297\u20132300, 10.1021\/jm070104l (2007).","journal-title":"Journal of medicinal chemistry"},{"key":"BFsrep12348_CR46","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.bcp.2005.04.009","volume":"70","author":"I Brandt","year":"2005","unstructured":"Brandt, I. et al. Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile). Biochemical pharmacology 70, 134\u2013143, 10.1016\/j.bcp.2005.04.009 (2005).","journal-title":"Biochemical pharmacology"},{"key":"BFsrep12348_CR47","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1210\/jc.2014-3794","volume":"100","author":"M Macauley","year":"2015","unstructured":"Macauley, M. et al. Effect of vildagliptin on hepatic steatosis. The Journal of clinical endocrinology and metabolism 100, 1578\u20131585, 10.1210\/jc.2014-3794 (2015).","journal-title":"The Journal of clinical endocrinology and metabolism"},{"key":"BFsrep12348_CR48","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.peptides.2006.09.027","volume":"28","author":"N Frerker","year":"2007","unstructured":"Frerker, N. et al. Neuropeptide Y (NPY) cleaving enzymes: structural and functional homologues of dipeptidyl peptidase 4. Peptides 28, 257\u2013268, 10.1016\/j.peptides.2006.09.027 (2007).","journal-title":"Peptides"},{"key":"BFsrep12348_CR49","doi-asserted-by":"publisher","first-page":"e36609","DOI":"10.1371\/journal.pone.0036609","volume":"7","author":"R Han","year":"2012","unstructured":"Han, R., Kitlinska, J. B., Munday, W. R., Gallicano, G. I. & Zukowska, Z. Stress hormone epinephrine enhances adipogenesis in murine embryonic stem cells by up-regulating the neuropeptide Y system. PloS one 7, e36609, 10.1371\/journal.pone.0036609 (2012).","journal-title":"PloS one"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep12348.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep12348","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep12348.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T14:28:42Z","timestamp":1672928922000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep12348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,5]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12,18]]}},"alternative-id":["BFsrep12348"],"URL":"https:\/\/doi.org\/10.1038\/srep12348","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,5]]},"assertion":[{"value":"10 February 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12348"}}